(Q37035285)

17 August 2017

1 reference

title

Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis (English)

1 reference

17 August 2017

0 references

1 reference

2

Yuri E Nikiforov

1 reference

17 August 2017

1

Marina N Nikiforova

1 reference

17 August 2017

1 January 2008

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

1

1 reference

17 August 2017

83-95

1 reference

Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee

17 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Mitogen-activated protein kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

BRAF mutation in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

BRAF mutations in an Italian cohort of thyroid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

BRAF is a therapeutic target in aggressive thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

New therapeutic approaches for metastatic thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Targeting BRAF in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

RET/PTC rearrangement in thyroid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

RET oncogene activation in papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Point mutations of ras oncogenes are an early event in thyroid tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Prevalence of activating ras mutations in morphologically characterized thyroid nodules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Genetic and biological subgroups of low-stage follicular thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Mutation of the PIK3CA gene in anaplastic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

A novel microdissection and genotyping of follicular-derived thyroid tumors to predict aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

INGN 201 (Advexin): adenoviral p53 gene therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Gene therapy for thyroid cancer: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Assignment of the human beta-catenin gene (CTNNB1) to 3p22-->p21.3 by fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Multistep carcinogenesis in anaplastic thyroid carcinoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Molecular biology of the MEN2 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

RET and NTRK1 proto-oncogenes in human diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.83

21 January 2018

Identifiers

DOI

10.1586/14737159.8.1.83

1 reference

17 August 2017

1 reference

PubMed ID

18088233